Nepal | July 08, 2020

Ebola ‘no longer incurable’ as Congo trial finds drugs boost survival

REUTERS
Share Now:

LONDON: Scientists are a step closer to being able to cure the deadly Ebola hemorrhagic fever after two experimental drugs showed survival rates of as much as 90% in a clinical trial in Congo.

Two experimental drugs – an antibody cocktail called REGN-EB3 developed by Regeneron (REGN.O) and a monoclonal antibody called mAb114 – will now be offered to all patients infected with the viral disease in an ongoing outbreak in the Democratic Republic of Congo (DRC).

The drugs showed “clearly better” results, according to US National Institute of Allergy and Infectious Diseases (NIAID), in a trial of four potential treatments being conducted during the second-largest Ebola outbreak in history, now entering its second year in DRC.

FILE PHOTO: A health worker fills a syringe with Ebola vaccine before injecting it to a patient, in Goma, Democratic Republic of Congo, August 5, 2019. Photo: Reuters

The drugs improved survival rates from the disease more than two other treatments being tested – ZMapp, made by Mapp Biopharmaceutical, and Remdesivir, made by Gilead Sciences (GILD.O) – and those products will be now dropped, said Anthony Fauci, one of the researchers co-leading the trial.

The agency said 49% of the patients on ZMapp and 53% on Remdesivir died in the study. In comparison, 29% of the patients on REGN-EB3 and 34% on mAb114 died.

Jean-Jacques Muyembe, director general of Congo’s Institut National de Recherche Biomédicale in DRC, who co-led the trial, said the results meant that “from now on, we will no longer say that Ebola is incurable.”

“These advances will help save thousands of lives,” he told reporters.

Anthony Fauci, NIAID’s director, also said the results were “very good news” for the fight against Ebola.

The agency said that of the patients who were brought into treatment centres with low levels of virus detected in their blood, 94% who got REGN-EB3 and 89% on mAb114 survived.

In comparison, two-thirds of the patients who got Remdesivir and nearly three-quarters on ZMapp survived.

Ebola has been spreading in eastern Congo since August 2018 in an outbreak that has now killed at least 1,800 people. Efforts to control it have been hampered by militia violence and some local resistance to outside help.

A vast Ebola outbreak in West Africa from 2013 to 2016 became the world’s largest-ever when it spread through Guinea, Liberia and Sierra Leone and killed more than 11,300 people.

The Congo treatment trial, which began in November last year, is being carried out by an international research group coordinated by the World Health Organization (WHO).

Mike Ryan, head of the WHO’s emergencies program, said the trial’s positive findings were encouraging but would not be enough on their own to bring the epidemic to an end.

“The news today is fantastic. It gives us a new tool in our toolbox against Ebola, but it will not in itself stop Ebola,” he told reporters.

Jeremy Farrar, director of the Wellcome Trust global health charity, also hailed the success of the trial’s findings, saying they would “undoubtedly save lives”.

“The more we learn about these two treatments … the closer we can get to turning Ebola from a terrifying disease to one that is preventable and treatable,” he said in a statement.

“We won’t ever get rid of Ebola but we should be able to stop these outbreaks from turning into major national and regional epidemics.”

Some 681 patients at four separate treatment centres in Congo have already been enrolled in the Congo treatment clinical trial, Fauci said. The study aims to enrol a total of 725.

The decision to drop two of the trial drugs was based on data from almost 500 patients, he said, which showed that those who got REGN-EB3 or mAb114 “had a greater chance of survival compared to those participants in the other two arms”.

The two promising drugs are made from Ebola antibodies – a protein produced by the immune system to defend against infection. Regeneron’s product is a cocktail of three Ebola antibodies, while mAb114 is a single antibody developed by scientists at NIAID.


Follow The Himalayan Times on Twitter and Facebook

Recommended Stories:

More from The Himalayan Times:

Transport entrepreneurs deposit vehicle keys at banks in Pokhara

POKHARA: After failing to deposit the loan installment in the wake of extended lockdown, transport entrepreneurs handed-over vehicle keys to bank officials in Pokhara, on Monday. As many as ninety entrepreneurs associated with Prithvi Highway Bus Association handed over the keys to officials Read More...

Protecting the Economically Vulnerable Population

Kathmandu, July 7 What started as a health crisis in the form of the COVID-19 pandemic has now unfolded into a global economic and livelihood crisis. While the ubiquitous quarantines and lockdowns may have saved many lives and provided an additional benefit of  environmental improvement, their e Read More...

Tottenham Hotspur

Keane own goal gives Spurs win over Everton

Keane own goal gives Spurs win Mourinho secures 200th Premier League win Son and Lloris have halftime bust-up LONDON: An own goal by Michael Keane proved the difference as Tottenham Hotspur beat visitors Everton 1-0 in a dour clash on Monday to move up to eighth in the standings an Read More...

Actor Depp takes on UK tabloid in court battle over 'wife beater' claims

LONDON: Johnny Depp begins legal action against a British tabloid on Tuesday in a case that is likely to delve into the private lives of the Hollywood star, his ex-wife actress Amber Heard and a number of other well-known figures. Depp, the 57-year-old star of the "Pirates of the Caribbean" f Read More...

Yanqi-Nepal meet China’s bid to keep NCP united?

Kathmandu, July 6 China’s Ambassador to Nepal Hou Yanqi yesterday met Madhav Kumar Nepal, a senior leader of the ruling Nepal Communist Party (NCP), raising eyebrows as the meeting took place at a time when the internal rift within the NCP is heading towards a climax. Nepal’s former perma Read More...

Student union asks guardians not to pay school fees

BHOJPUR, JULY 6 Nepal Student Union, Bhojpur, has asked guardians not to pay any fees to schools for the lockdown period. At a time when PABSON and N-PAB- SON have asked guardians to pay fees to schools even for the lockdown period, NSU, Bhojpur, has asked guardians not to pay fees for the loc Read More...

175 suicide deaths in Sudurpaschim during lockdown

DADELDHURA, JULY 6 As many as 175 people have died by suicide during the nationwide lockdown in Sudurpaschim Province. Police said that suicide deaths have been reported from all nine districts of the province from March 24 till date. Police said suicide deaths were more common among males com Read More...

Indian side admits constructing embankment in Dasgaja area

RAUTAHAT, JULY 6 A joint survey team of Nepal and India gauged the Dasgaja area with a global positioning system which showed that the Indian side had constructed an embankment on 200 metres of encroached land in Dasgaja area. India had built a 10-metre tall embankment at Banjaraha of Ishnath Read More...